Skip to main content

Advertisement

Table 2 Tumor histology

From: Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Tumor histology 1 mg/kg 3 mg/kg 10 mg/kg Total
Melanoma 10 10 2 22
Urothelial carcinoma 3 2 3 8
Renal cell carcinoma 2 3 1 6
Total 15 15 6 36
  1. Total 36 subjects were enrolled in the trial, including 22 melanomas, 8 urothelial carcinomas, and 6 renal cell carcinomas in three JS001 dose cohorts of 1 mg/kg (n = 15), 3 mg/kg (n = 15), and 10 mg/kg (n = 6) given via intravenously infusion every 2 weeks (Q2W)